Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Jun;40(6):1412–1418. doi: 10.1128/aac.40.6.1412

In vitro activities of quinolones, beta-lactams, tobramycin, and trimethoprim-sulfamethoxazole against nonfermentative gram-negative bacilli.

R J Fass 1, J Barnishan 1, M C Solomon 1, L W Ayers 1
PMCID: PMC163341  PMID: 8726011

Abstract

From 1991 to 1995, 8,975 nonfermentative gram-negative bacilli were isolated from patients at The Ohio State University Medical Center: 71% Pseudomonas aeruginosa, 14% Stenotrophomonas maltophilia, 7.6% Acinetobacter baumannii, and < 2% each of 25 other species. The MICs of trovafloxacin (CP-99,219), ciprofloxacin, ofloxacin, ampicillin-sulbactam, piperacillin, piperacillin-tazobactam, ceftazidime, cefoperazone, ceftriaxone, imipenem, tobramycin, and trimethoprim-sulfamethoxazole (TMP-SMZ) were determined for 308 isolates, representing 13 species, by a standardized broth microdilution method. The activities of all drugs were species dependent. The fluoroquinolones had inconsistent activity against most species, although several relatively uncommon nonfermenters were consistently susceptible or resistant. Trovafloxacin was considerably more active than ciprofloxacin and ofloxacin against S. maltophilia, A. baumannii, and several less common species. Among the beta-lactams, relative activities varied considerably; overall, imipenem had the broadest spectrum of activity but was inactive against S. maltophilia and Burkholderia cepacia isolates. Tobramycin and TMP-SMZ had stereotypic spectra of activity. Tobramycin was active against most species except S. maltophilia, Alcaligenes xylosoxidans subsp. xylosoxidans, Burkholderia spp., and Weeksella virosa. TMP-SMZ was active against most species except P. aeruginosa and Pseudomonas fluorescens-putida. A review of laboratory records indicated few changes in susceptibility patterns from 1991 to 1995; the only clear trend was toward increasing P. aeruginosa resistance to all classes of drugs.

Full Text

The Full Text of this article is available as a PDF (309.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Appelbaum P. C., Spangler S. K., Tamarree T. Susceptibility of 310 nonfermentative gram-negative bacteria to aztreonam, carumonam, ciprofloxacin, ofloxacin and fleroxacin. Chemotherapy. 1988;34(1):40–45. doi: 10.1159/000238546. [DOI] [PubMed] [Google Scholar]
  2. Bruckner D. A., Colonna P. Nomenclature for aerobic and facultative bacteria. Clin Infect Dis. 1995 Aug;21(2):263–272. doi: 10.1093/clinids/21.2.263. [DOI] [PubMed] [Google Scholar]
  3. Child J., Andrews J., Boswell F., Brenwald N., Wise R. The in-vitro activity of CP 99,219, a new naphthyridone antimicrobial agent: a comparison with fluoroquinolone agents. J Antimicrob Chemother. 1995 Jun;35(6):869–876. doi: 10.1093/jac/35.6.869. [DOI] [PubMed] [Google Scholar]
  4. Fass R. J., Barnishan J., Ayers L. W. Emergence of bacterial resistance to imipenem and ciprofloxacin in a university hospital. J Antimicrob Chemother. 1995 Aug;36(2):343–353. doi: 10.1093/jac/36.2.343. [DOI] [PubMed] [Google Scholar]
  5. Fass R. J., Barnishan J. In vitro susceptibilities of nonfermentative gram-negative bacilli other than Pseudomonas aeruginosa to 32 antimicrobial agents. Rev Infect Dis. 1980 Nov-Dec;2(6):841–853. doi: 10.1093/clinids/2.6.841. [DOI] [PubMed] [Google Scholar]
  6. Fass R. J., Gregory W. W., D'Amato R. F., Matsen J. M., Wright D. N., Young L. S. In vitro activities of cefoperazone and sulbactam singly and in combination against cefoperazone-resistant members of the family Enterobacteriaceae and nonfermenters. Antimicrob Agents Chemother. 1990 Nov;34(11):2256–2259. doi: 10.1128/aac.34.11.2256. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Fass R. J. In vitro activity of cefoperazone against nonfermenters and Aeromonas hydrophila. Antimicrob Agents Chemother. 1980 Sep;18(3):483–486. doi: 10.1128/aac.18.3.483. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Fass R. J., Prior R. B. Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate. Antimicrob Agents Chemother. 1989 Aug;33(8):1268–1274. doi: 10.1128/aac.33.8.1268. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Fass R. J. Statistical comparison of the antibacterial activities of broad-spectrum penicillins against gram-negative bacilli. Antimicrob Agents Chemother. 1983 Aug;24(2):156–162. doi: 10.1128/aac.24.2.156. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Fass R. J. Use of frequency distribution curves, scattergrams and regression analyses to compare in vitro activities and describe cross-susceptibility and cross-resistance among four quinolones. J Chemother. 1994 Dec;6(6):368–376. doi: 10.1080/1120009x.1994.11736491. [DOI] [PubMed] [Google Scholar]
  11. Gooding B. B., Jones R. N. In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone. Antimicrob Agents Chemother. 1993 Feb;37(2):349–353. doi: 10.1128/aac.37.2.349. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Kessler R. E., Fung-Tomc J., Kolek B., Minassian B., Huczko E., Gradelski E., Bonner D. P. In vitro activity of BMS-181139, a new carbapenem with potent antipseudomonal activity. Antimicrob Agents Chemother. 1995 Feb;39(2):380–385. doi: 10.1128/aac.39.2.380. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Neu H. C., Chin N. X. In vitro activity of the new fluoroquinolone CP-99,219. Antimicrob Agents Chemother. 1994 Nov;38(11):2615–2622. doi: 10.1128/aac.38.11.2615. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Nicoletti G., Stefani S. Survey on antibiotic resistance in gram-negative non-fermentative bacteria other than pseudomonas in Italy. J Chemother. 1994 Feb;6(1):20–24. doi: 10.1080/1120009x.1994.11741123. [DOI] [PubMed] [Google Scholar]
  15. O'Donnell E. D., Freimer E. H., Gilardi G. L., Raeder R. Comparative in vitro activities of N-formimidoyl thienamycin and moxalactam against nonfermentative aerobic gram-negative rods. Antimicrob Agents Chemother. 1982 Apr;21(4):673–675. doi: 10.1128/aac.21.4.673. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Strandberg D. A., Jorgensen J. H., Drutz D. J. Activities of aztreonam and new cephalosporins against infrequently isolated gram-negative bacilli. Antimicrob Agents Chemother. 1983 Aug;24(2):282–286. doi: 10.1128/aac.24.2.282. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Teng R., Harris S. C., Nix D. E., Schentag J. J., Foulds G., Liston T. E. Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers. J Antimicrob Chemother. 1995 Aug;36(2):385–394. doi: 10.1093/jac/36.2.385. [DOI] [PubMed] [Google Scholar]
  18. Yabuuchi E., Ito T., Tanimura E., Yamamoto N., Ohyama A. In vitro antimicrobial activity of ceftizoxime against glucose-nonfermentative gram-negative rods. Antimicrob Agents Chemother. 1981 Jul;20(1):136–139. doi: 10.1128/aac.20.1.136. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES